Johnson & Johnson Tops Profit Expectations, Lifts Outlook Following Price
Increases To Start the Year





 



BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Johnson & Johnson Tops Profit Expectations, Lifts Outlook Following Price
Increases To Start the Year



This week, Big Pharma giant Johnson & Johnson posted second-quarter earnings
<[link removed]>
that surpassed Wall Street expectations. The strong earnings report follows
the company hiking prices on at least28 prescription drugs
<[link removed]> so far this year. Johnson &
Johnson raised their full year sales guidance to between $100.8 billion to
$101.4 billion, an increase from the previous quarter. Johnson & Johnson has
consistently topped earnings expectations for years, while continuing to
increase prices across its portfolio.



Get a full recap of Johnson & Johnson’s latest earnings here:



Johnson & Johnson

* Johnson & Johnson reported second quarter earnings
<[link removed]>
that topped Wall Street expectations.
* In the second quarter, the Big Pharma company’s oncology drug, Darzalex,
brought in sales of$4.2 billion
<[link removed]>.
* The company’s psoriasis drug, Tremfya, brought in $2 billion
<[link removed]> in
sales, compared to estimates of $1.74 billion.
* Johnson & Johnson now expects full-year sales of $100.8 billion to $101.4
billion
<[link removed]>
.
Johnson & Johnson’s earnings reflect a continuing pattern of egregious pricing
practices across its top-selling blockbuster drugs.


Johnson & Johnson

* Johnson & Johnson has hiked prices on 28 prescription drugs
<[link removed]> so far in 2026, including a
five percent increase on psoriasis drug Stelara.
* Johnson & Johnson hiked prices on 30 prescription drugs
<[link removed]> in 2025, including a 5.5
percent increase on multiple myeloma drug Darzalex and a 4.7 percent increase
on psoriasis drug Stelara.
* Johnson & Johnson engaged in 34 price hikes
<[link removed]> in 2024, including a 4.8
percent increase on Darzalex, and five percent increases on Erleada and Stelara.
* According to a December 2024 ICER report
<[link removed]>, price
hikes that were unsupported by new clinical evidence on the multiple myeloma
drug Darzalex led to additional consumer spending of$190 million
<[link removed]>.
* Johnson & Johnson also engaged in 36 price hikes
<[link removed]> in 2023, including a 4.5
percent increase on Darzalex, a five percent increase on Erleada and a 4
percent increase on Stelara.
* Spending on the company’s blockbuster cancer drug Imbruvica is expected to
exceed $41 billion <[link removed]> between 2027 and 2036,
thanks to an anti-competitive patent scheme that extended a monopoly on the
high-priced cancer drug by more than nine years. Imbruvica costs an eye-popping
$180,000 per year
<[link removed]>
.
Stay tuned as we continue to monitor second quarter earnings calls from brand
name drug companies in the coming weeks.



Learn more about solutions to lower prescription drug prices and hold Big
Pharma accountableHERE <[link removed]>.



###





























Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>